179 related articles for article (PubMed ID: 16354015)
1. Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient.
Asthana A; Chauhan AS; Diwan PV; Jain NK
AAPS PharmSciTech; 2005 Oct; 6(3):E536-42. PubMed ID: 16354015
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of polyamidoamine dendrimers as potential carriers for quercetin, a versatile flavonoid.
Madaan K; Lather V; Pandita D
Drug Deliv; 2016; 23(1):254-62. PubMed ID: 24845475
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic studies of poly(amidoamine) dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia.
Kulhari H; Kulhari DP; Prajapati SK; Chauhan AS
Mol Pharm; 2013 Jul; 10(7):2528-33. PubMed ID: 23692066
[TBL] [Abstract][Full Text] [Related]
4. Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers.
Cheng Y; Man N; Xu T; Fu R; Wang X; Wang X; Wen L
J Pharm Sci; 2007 Mar; 96(3):595-602. PubMed ID: 17094130
[TBL] [Abstract][Full Text] [Related]
5. Folate coupled poly(ethyleneglycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery.
Chandrasekar D; Sistla R; Ahmad FJ; Khar RK; Diwan PV
J Biomed Mater Res A; 2007 Jul; 82(1):92-103. PubMed ID: 17269145
[TBL] [Abstract][Full Text] [Related]
6. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats.
Chauhan AS; Jain NK; Diwan PV; Khopade AJ
J Drug Target; 2004; 12(9-10):575-83. PubMed ID: 15621683
[TBL] [Abstract][Full Text] [Related]
7. Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers.
Yiyun C; Tongwen X
Eur J Med Chem; 2005 Nov; 40(11):1188-92. PubMed ID: 16153746
[TBL] [Abstract][Full Text] [Related]
8. All-atomistic molecular dynamics (AA-MD) studies and pharmacokinetic performance of PAMAM-dendrimer-furosemide delivery systems.
Otto DP; de Villiers MM
Int J Pharm; 2018 Aug; 547(1-2):545-555. PubMed ID: 29908331
[TBL] [Abstract][Full Text] [Related]
9. Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of piroxicam.
Prajapati RN; Tekade RK; Gupta U; Gajbhiye V; Jain NK
Mol Pharm; 2009; 6(3):940-50. PubMed ID: 19231841
[TBL] [Abstract][Full Text] [Related]
10. Poly (amidoamine) dendrimer-mediated hybrid formulation for combination therapy of ramipril and hydrochlorothiazide.
Singh MK; Pooja D; Kulhari H; Jain SK; Sistla R; Chauhan AS
Eur J Pharm Sci; 2017 Jan; 96():84-92. PubMed ID: 27614111
[TBL] [Abstract][Full Text] [Related]
11. Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.
Gu Z; Wang M; Fang Q; Zheng H; Wu F; Lin D; Xu Y; Jin Y
Drug Dev Ind Pharm; 2015 May; 41(5):812-8. PubMed ID: 24745851
[TBL] [Abstract][Full Text] [Related]
12. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid.
Wiwattanapatapee R; Lomlim L; Saramunee K
J Control Release; 2003 Feb; 88(1):1-9. PubMed ID: 12586498
[TBL] [Abstract][Full Text] [Related]
13. Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent.
Agarwal A; Gupta U; Asthana A; Jain NK
Biomaterials; 2009 Jul; 30(21):3588-96. PubMed ID: 19344947
[TBL] [Abstract][Full Text] [Related]
14. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin.
Durairaj C; Kadam RS; Chandler JW; Hutcherson SL; Kompella UB
Invest Ophthalmol Vis Sci; 2010 Nov; 51(11):5804-16. PubMed ID: 20484584
[TBL] [Abstract][Full Text] [Related]
15. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly(amidoamine) dendrimers.
Chauhan AS; Diwan PV; Jain NK; Tomalia DA
Biomacromolecules; 2009 May; 10(5):1195-202. PubMed ID: 19348417
[TBL] [Abstract][Full Text] [Related]
16. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes.
Devarakonda B; Otto DP; Judefeind A; Hill RA; de Villiers MM
Int J Pharm; 2007 Dec; 345(1-2):142-53. PubMed ID: 17600643
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam.
Khurana S; Jain NK; Bedi PM
Life Sci; 2013 Nov; 93(21):763-72. PubMed ID: 24113071
[TBL] [Abstract][Full Text] [Related]
18. Association of the anti-tuberculosis drug rifampicin with a PAMAM dendrimer.
Bellini RG; Guimarães AP; Pacheco MA; Dias DM; Furtado VR; de Alencastro RB; Horta BA
J Mol Graph Model; 2015 Jul; 60():34-42. PubMed ID: 26093506
[TBL] [Abstract][Full Text] [Related]
19.
Nazlı H; Gedik G
Pharm Dev Technol; 2021 Sep; 26(7):750-764. PubMed ID: 34154500
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine-PAMAM Conjugates for Improved Apoptosis, Efficacy, and in Vivo Pharmacokinetics: A Sustainable Delivery Tactic.
Gothwal A; Khan I; Kumar P; Raza K; Kaul A; Mishra AK; Gupta U
Mol Pharm; 2018 Jun; 15(6):2084-2097. PubMed ID: 29195048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
